Commercial Credit Report for Zogenix, Inc.

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Zogenix, Inc. is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zogenix, Inc.

5959 Horton St Ste 500

Phone: (510) 550-8300p:510 550-8300

EMERYVILLE, CA 94608-2120 United States

Fax: (858) 259-1166f:858 259-1166

This company was Merged or Acquired on 3/7/2022.

This company ceased filing statements with the SEC on 3/17/2022.

This company is no longer actively traded on any major stock exchange.

This is a Subsidiary, click here for the Parent Company

Business Summary

Zogenix, Inc. is a global biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.

(Source: 10-K)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2021	12/31/2021	Yes	Yes	-	-	Yes

Industries

SIC Code	Description
2834	Pharmaceutical preparations
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Independent Chairman of the Board	Cam L.Garner	72	8/1/2006	8/1/2006
President, Chief Executive Officer, Director	Stephen J.Farr	62	4/27/2015	5/1/2006
Chief Financial Officer, Executive Vice President, Treasurer, Secretary	Michael P.Smith	52	1/16/2017	1/16/2017
8 additional Officers and Directors records available in full report.

Business Names

Business Name
0M3O
Brabant Pharma Limited
ZGNX
9 additional Business Names available in full report.

General Information

Number of Employees:	327	(As of 12/31/2021)
Outstanding Shares:	56,228,303	(As of 2/28/2022)
Shareholders:	9
Stock Exchange:	NASD
Federal Tax Id:	205300780
Fax Number:	(858) 259-1166

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN